Plain-English translation of NCT07133490 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining intraperitoneal irinotecan — a chemotherapy drug delivered directly into the abdominal cavity — together with standard chemotherapy pills or infusions can help patients with gastric cancer that has spread to the peritoneum (the lining of the abdomen). Depending on your cancer's characteristics, you may also receive targeted therapies like nivolumab or trastuzumab. The goal is to see whether this combination approach is safe, feasible, and effective.
Stomach cancer that spreads to the lining of the abdomen is very difficult to treat with standard chemotherapy alone. By delivering chemotherapy directly into the abdomen where the cancer is, doctors hope this medication may work better and help patients live longer.
You likely qualify if…
You likely don't qualify if…
You would visit one of three hospitals in the Netherlands regularly to receive the treatment. The intraperitoneal irinotecan would be delivered directly into your abdomen, likely during a minor procedure, while you also receive standard chemotherapy through an IV or by mouth at home. You may have blood tests, imaging scans, and clinical visits to monitor how well the treatment is working and to watch for side effects. The trial involves 55 patients total across the three hospitals.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Netherlands